On October 16, 2025, Theriva Biologics, Inc. entered into an agreement allowing holders to exercise existing warrants for 8,092,280 shares at $0.54 each, providing approximately $4.4 million in proceeds, and issuing new warrants for 16,184,560 shares. This agreement is considered significant for the company.